| Literature DB >> 32523360 |
Ye Xu1, Xiangkuo Zheng2, Weiliang Zeng2, Tao Chen1, Wenli Liao1, Jiao Qian1, Jie Lin1, Cui Zhou1, Xuebin Tian2, Jianming Cao2, Tieli Zhou1.
Abstract
BACKGROUND: Heteroresistance is a phenomenon that occurs in all bacteria and can cause treatment failure. Yet, the exact mechanisms responsible for heteroresistance still remain unknown. The following study investigated the mechanisms of imipenem-heteroresistance and -resistance in Pseudomonas aeruginosa clinical isolates from Wenzhou, China.Entities:
Keywords: Pseudomonas aeruginosa; heteroresistance; imipenem; molecular mechanism; oprD; resistance
Year: 2020 PMID: 32523360 PMCID: PMC7234976 DOI: 10.2147/IDR.S249475
Source DB: PubMed Journal: Infect Drug Resist ISSN: 1178-6973 Impact factor: 4.003
Characteristics of Heteroresistant Isolates Determined Using PAP, MICs of Imipenem and Levels of Biofilm Formation
| Strain | MIC of Native Population (μg/mL) | Highest Drug Concentration in PAP (μg/mL) | Heterogeneous Subpopulation MIC After Free-Drug Subcultures (μg/mL) | Frequency of Resistant Subpopulations in Highest Drug Concentration | Biofilm Formation (OD595) | ||
|---|---|---|---|---|---|---|---|
| Native Population | Subpopulation | ||||||
| TL-2856 | 1 | 8 | 8 | 5.3×10−6 | 0.46±0.08 0.98±0.15 0.0001 | ||
| TL-2862 | 1 | 4 | 8 | 3.8×10−6 | 0.65±0.03 0.66±0.09 0.78 | ||
| TL-2870 | 1 | 8 | 16 | 8.0×10−7 | 0.64±0.13 0.69±0.09 0.94 | ||
| TL-2872 | 2 | 4 | 16 | 4.2×10−7 | 0.45±0.12 0.54±0.02 0.17 | ||
| TL-2873 | 2 | 4 | 8 | 2.8×10−7 | 0.61±0.24 0.62±0.09 0.9 | ||
| TL-2877 | 2 | 8 | 16 | 2×10−7 | 0.37±0.04 0.45±0.08 0.14 | ||
The Profile of Routine Antibacterial Resistance in P. aeruginosa
| Strain | MICs of Clinical Routine Antimicrobial Agents (μg/mL) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| IPM | MEM | AMK | CAZ | CIP | LVX | TOB | TZP | FEP | |
| TL-2856 | a1 | 0.25 | 1 | 2 | ≤0.125 | 0.25 | 0.5 | 8/4 | 2 |
| b8 | 2 | 2 | 2 | ≤0.125 | 0.5 | 0.5 | 4/4 | 2 | |
| TL-2862 | a1 | 1 | 2 | 2 | ≤0.125 | 0.5 | 0.5 | 4/4 | 1 |
| b8 | 4 | 2 | 2 | ≤0.125 | 0.5 | 0.5 | 4/4 | 2 | |
| TL-2870 | a1 | 0.25 | 2 | 2 | ≤0.125 | 0.25 | 1 | 4/4 | 1 |
| b16 | 4 | 2 | 2 | ≤0.125 | 0.25 | 1 | 4/4 | 2 | |
| TL-2872 | a2 | 1 | 1 | 4 | ≤0.125 | 0.5 | 1 | 8/4 | 4 |
| b16 | 8 | 1 | 4 | 0.25 | 0.5 | 1 | 8/4 | 4 | |
| TL-2873 | a2 | 1 | 2 | 2 | ≤0.125 | 0.5 | 1 | 8/4 | 4 |
| b8 | 4 | 2 | 2 | ≤0.125 | 0.5 | 1 | 8/4 | 4 | |
| TL-2877 | a2 | 0.25 | 2 | 2 | ≤0.125 | 0.5 | 1 | 2/4 | 1 |
| b16 | 4 | 4 | 2 | ≤0.125 | 0.25 | 1 | 4/4 | 1 | |
| TL-2854 | 8 | 4 | 4 | 2 | 0.25 | 1 | 1 | 4/4 | 8 |
| TL-2858 | 16 | 4 | 2 | 64 | 0.5 | 2 | 0.5 | ≥128/4 | 32 |
| TL-2859 | 16 | 4 | 8 | 2 | 1 | 1 | 32 | 4/4 | 8 |
| TL-2878 | 16 | 4 | 2 | 64 | 0.5 | 1 | 0.5 | ≥128/4 | 16 |
| TL-2958 | 16 | 4 | 4 | 4 | 0.5 | 1 | 2 | 4/4 | 4 |
| TL-2997 | 8 | 4 | 2 | 2 | 0.25 | 0.5 | 1 | 4/4 | 4 |
| TL-2874 | 1 | 0.25 | 4 | 2 | 0.25 | 0.5 | 1 | 4/4 | 2 |
| TL-2875 | 1 | 0.125 | 2 | 2 | 0.25 | 0.5 | 0.5 | 4/4 | 2 |
| TL-2891 | 1 | 0.25 | 4 | 4 | ≤0.125 | 0.5 | 1 | 4/4 | 2 |
| TL-2892 | 1 | ≤0.125 | 1 | 1 | ≤0.125 | 0.25 | 0.5 | 2/4 | 1 |
| TL-2907 | 1 | 0.125 | 4 | 2 | ≤0.125 | 0.25 | 2 | 4/4 | 2 |
| TL-2908 | 1 | 0.5 | 4 | 32 | ≤0.125 | 0.25 | 1 | 128/4 | 2 |
Notes: aSusceptible population; bheteroresistant subpopulation; resistant and susceptible strains were shown in blue shading and gray shading, respectively.
Abbreviations: MEM, meropenem; AMK, amikacin; CAZ, ceftazidime; CIP, ciprofloxacin; LVX, levofloxacin; TOB, tobramycin; TZP, piperacillin/tazobactam; FEP, cefepime.
Figure 1Levels of biofilm formation between wild-type susceptible and resistant isolates. IPM-WTS, wild-type imipenem susceptibility strains; IPM-WTR, wild-type imipenem resistance strains.
Figure 2oprD mutations in imipenem-(hetero) resistant P. aeruginosa clinical isolates. aIn imipenem-heteroresistant populations (IPM-HRP); bwild-type imipenem resistant isolates (IPM-WTR); ctwo 3 bp deletion at nucleotide 1116–1118 and nucleotide 1147–1149 in external loop7; d1 bp deletion at nucleotide 348; e379 bp deletion at nucleotide 410–788; f1 bp deletion at nucleotide 917; g1251G > A; h15 bp deletion at nucleotide 256–270; *premature stop codon; blue circle, amino acid substitutions were detected in wild-type imipenem susceptible isolates and native imipenem susceptible populations of heteroresistance and the amino acid substitutions were predicted neutral using ; orange circle, oprD mutation only was detected in heteroresistance and resistance.
Figure 3Expression levels of genes in heteroresistant subpopulations. (A) Expression levels of oprD. (B) Expression levels of ampC. (C) Expression levels of mexB. (D) Expression levels of mexD. (E) Expression levels of mexE. (F) Expression levels of mexY. IPM-SP, native imipenem-susceptible populations; IPM-HRP, imipenem-heteroresistant subpopulations; *P < 0.05.
Figure 4Expression levels of genes in wild-type susceptible and resistant isolates. IPM-WTS, wild-type imipenem-susceptible strains; IPM-WTR, wild-type imipenem-resistant strains; PAO1 was served as standardized strain *P < 0.05.